OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine

Drug Metabolism and Disposition

Volumn 27, Issue 8, 1999, Pages 866-871

  Cvetkovic, Mirjana ^a   Leake, Brenda ^a   Fromm, Martin F ^a   Wilkinson, Grant R ^a   Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE; GLYCOPROTEIN P;

ANIMAL CELL; ARTICLE; CELL TRANSPORT; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; DRUG UPTAKE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANION TRANSPORT PROTEINS; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CARRIER PROTEINS; GENES, MDR; HELA CELLS; HISTAMINE H1 ANTAGONISTS; HUMANS; LLC-PK1 CELLS; MICE; P-GLYCOPROTEIN; RATS; SWINE; TERFENADINE; TISSUE DISTRIBUTION; TRANSFECTION; VACCINIA VIRUS;

EID: 0032793959     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bossuyt X, Müller M, Hagenbuch B and Meier PJ (1996) Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Phamacol Exp Ther 276:891-896.
2. Childs S, Yeh RL, Georges E and Ling V (1995) Identification of a sister gene to p-glycoprotein. Cancer Res 55:2029-2034.
3. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley HG (1992) Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line. Science (Wash DC) 258:1650-1654.
4. Eckhardt U, Horz JA, Petzinger E, Stüber W, Reers M, Dickneite G, Daniel H, Wagener M, Hagenbuch B, Stieger B and Meier PJ (1996) The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide. Hepatology 24:380-384.
5. Fromm MF, Kim RB, Stein CM, Wilkinson GR and Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557.
6. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF and Meier PJ (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273:10046-10050.
7. +-independent organic anion transporter. Proc Natl Acad Sci USA 91:133-137.
8. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
9. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJJ and Wilkinson GR (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414.
10. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F and Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547.
11. Kullak-Ublick G-A, Hagenbuch B, Stieger B, Schteingart CD, Hoffmann AF, Wolkoff AW and Meier PJ (1995) Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109:1274-1284.
12. Levêque D and Jehl F (1995) P-glycoprotein and pharmacokinetics. Anticancer Res 15:331-336.
13. Lippert C, Ling J, Brown P, Burmaster S, Eller M, Cheng L, Thompson R and Weir S (1995) Mass balance and pharmacokinetics of MDL 16455A in healthy male volunteers. Pharm Res 12:S390.
14. Markham A and Wagstaff AJ (1998) Fexofenadine. Drugs 55:269-274.
15. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKF, van Asperen J, Borst P and Schinkel AH (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrla P-glycoprotein. Br J Pharmacol 119:1038-1044.
16. Noé B, Hagenbuch B, Stieger B and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94:10346-10350.
17. Pastan I and Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42:277-286.
18. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P (1994) Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
19. Schinkel AH, Wagenaar E, Mol CAAM and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
20. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM and Borst P (1995) Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
21. +-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol 274:G370-G375.
22. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
23. Woosley RL, Chen Y, Freiman JP and Gillis RA (1993) Mechanism of the cardiotoxic actions of terfenadine. J Am Med Assoc 269:1532-1536.